New therapeutic opportunity for the treatment of resistant malignant melanoma

Source: eCancer, June 2018

A team of researchers led by Dr Pierre Close, WELBIO researcher at the ULiège GIGA Institute and Dr Francesca Rapino has uncovered a new therapeutic opportunity in the treatment of malignant melanoma that acquired resistance to targeted therapies.

In collaboration with researchers from VIB, they have revealed that malignant melanoma can reprogram their protein synthesis machinery and become addicted to a new family of enzymes that modify transfer RNAs during acquired resistance.